From a translational perspective, we demonstrate that there is no compensatory upregulation of the other NBEs (NAPRT, QPRT and NRK) in response to NAMPT repression, supporting the possibility of clinical use of the inhibitors, in combination with BRAFi/MEKi, for this subset of cancer patients, addicted to NAMPT activity. This evidence concerns the gene QPRT and cancer.